Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

- First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion -

ORLANDO, Fla., March 30 /PRNewswire/ -- Amorcyte, Inc. (Amorcyte) today announced data from its Phase I clinical trial of AMR-001, the company's lead product for the treatment of damaged heart muscle following acute myocardial infarction (AMI), that showed a significant relationship between cell dose and biologic effect. This is the first and only study to prospectively define a dose of a purified and potent autologous stem cell therapy (AMR-001) that resulted in a significant improvement in perfusion, a trend towards improved cardiac function and the potential to reduce subsequent adverse cardiac events following AMI. The findings were presented at the American College of Cardiology (ACC) Annual Scientific Session.

The 31 patients in the Phase I trial were randomly assigned to an autologous stem cell harvest group (cells were harvested from the patient's own bone marrow) or control group five days after an ST elevation myocardial infarction (STEMI) characterized by a prolonged period of hypoperfusion (blocked blood supply). CD34+ cells were then isolated from the bone marrow, and enriched to increase potency using the company's patented technology into five, 10 and 15 million cell doses. The cells were infused via the infarct-related artery seven to 11 days following the STEMI - the optimal time frame to attempt to prevent adverse ventricular remodeling. Caused by the progressive decline in heart muscle function following an AMI, ventricular remodeling can lead to permanent heart damage and increase the risk of recurrent heart attack, other adverse cardiac events and death.

The study results showed that patients receiving 10 to 15 million cells (n=9) experienced significant improvement in resting perfusion rates at six months as compared to patients receiving 5 million cells (n=6) and control (n=15), as measu
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , , SAN MATEO, Calif., Nov. 24 /PRNe...X ), a biopharmaceutical company focused on develo...rapies, announced today that Anthony DiTonno, Pres... present at the 21st Annual Piper Jaffray Health C...he New York Palace Hotel in New York, New York. ,...
(Date:11/24/2009)... , , , Primary efficacy endpoint has ...ecurrent endometrial cancer, , QUEBEC CITY, N...nc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a ...ine therapy and oncology, today announced positive...ted cytotoxic peptide conjugate, AEZS-108 (formerl...
(Date:11/24/2009)... , , REDWOOD CITY, Calif., Nov. 24 /PRN...: GHDX ) today announced that Randy Scott, Genomi... 21st Annual Piper Jaffray Health Care Conference ...0:00 a.m. ET. ,, To access the live and subseq... the Investor Relations section of Genomic Health,...
(Date:11/24/2009)... , , SEATTLE, Nov. 24 /PRNewswire-Fir...nd MTA: CTIC) management will present at the 21st ...onference will be held December 1-2, 2009, at the ... Tuesday, December 1 at 11:00 a.m. Eastern Time in...,s presentation will be available at www.cellther...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...f Standards and Technology (NIST) have made the fi...sion and collapse of thin polymer films used in th...ts a matter of only a couple of nanometers, but it...eneration chip manufacturing. The NIST measurement...nto the complex chemistry that enables the mass pr...
... CARLSBAD, Calif., Dec. 12 Genoptix, Inc.,(Nasdaq...er, today reported,revenues of $16.2 million for t...ase of 134% over revenues of $6.9 million for the ...ed September 30, 2007, the Company reported,revenu...nues of $16.2,million for the comparable period in...
...Inc. (Nasdaq: ARNA ) today announced that Phillip...to its board of directors. Mr. Schneider and Mr.,W...rectors and bring,significant financial and biotec...nce to Arena,s board of directors. Arena,s board a... and Mr. Woods to its Corporate Governance,and Nom...
Other Biology Technology:New paper reveals nanoscale details of photolithography process 2Genoptix Reports Strong Financial Results For Third Quarter 2007 2Genoptix Reports Strong Financial Results For Third Quarter 2007 3Genoptix Reports Strong Financial Results For Third Quarter 2007 4Genoptix Reports Strong Financial Results For Third Quarter 2007 5Genoptix Reports Strong Financial Results For Third Quarter 2007 6Genoptix Reports Strong Financial Results For Third Quarter 2007 7Genoptix Reports Strong Financial Results For Third Quarter 2007 8Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors 2Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors 3
(Date:11/23/2009)...- More than 160 participants gathered this week fo...ES INITIATIVE conference. This year,s topic, "Synt...eers, and medical researchers to explore the engin...the emerging field of synthetic biology. , Bonni...inceton University and this year,s conference chai...
(Date:11/23/2009).... A new study provides "incontrovertible evidence...island of Sumatra about 73,000 years ago deforeste... epicenter, researchers report. , The volcano ej...o the atmosphere, leaving a crater (now the world,...ng and 35 kilometers wide. Ash from the event has ...
(Date:11/23/2009).... - By producing some of the highest resolution im...ientists have a deeper understanding how biomolecu...may lead to a new treatment for kidney stones usin... the Nov. 23 online edition of the journal Procee...es how peptides interact with mineral surfaces by ...
Breaking Biology News(10 mins):Synthetic biology offers new opportunities for interdisciplinary collaboration 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3ALPCO Launches GLP 1 28Active 7 36 29 and 287 36 and 9 36 29 ELISA Kits 57959 1ALPCO Launches GLP 1 28Active 7 36 29 and 287 36 and 9 36 29 ELISA Kits 57959 2New multi use device can shed light on oxygen intake 57958 1New multi use device can shed light on oxygen intake 57958 2To regenerate muscle cellular garbage men must become builders 57953 1To regenerate muscle cellular garbage men must become builders 57953 2
...ss and what does it do? It stops eating. Humans sh...stress they often head for the refrigerator, produ...s, which are normally solitary, are placed in a gr...ientists at the Center for Behavioral Neuroscience... a model for human stress-induced obesity. They wa...
...st a few calories from the daily diet can do more ... help lessen the effects of aging. , Scientists fr...have found that eating a little less food and exer... even reverse aging-related cell and organ damage ... the journal Antioxidants and Redox Signaling, bui...
... way insects, plants and animals overcome engineer...nergy, according to new research published in the ... engineering difficulties, such as lifting a load ... of man-made technologies manipulate energy, often...he problem. , However, new research which has com...
Other Biology News:Just like us, social stress prompts hamsters to overeat, gain weight 2Just like us, social stress prompts hamsters to overeat, gain weight 3Just like us, social stress prompts hamsters to overeat, gain weight 4Cutting calories slightly can reduce aging damage 2Cutting calories slightly can reduce aging damage 3Copying nature could save us energy, study shows 2
Coverslips for Microarrays from GE Healthcare, formerly Amersham Biosciences
Argarase from BioVision
Rabbit Anti-HALOPERIDOL Polyclonal Antibody, Unconjugated from AbD Serotec
...tain stiffness in liquids, protect against acciden...segments on each strip have chemically bonded dyes...or charts provide clear comparison. Full-range str...100; each strip is approximately 1/4 x 3 in. (6 x ...
Biology Products: